We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+25.81%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$241M
AUM Growth
+$50.3M
Cap. Flow
+$11.8M
Cap. Flow %
4.88%
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17

Top Buys

Rank Stock Value
1
BEPC icon
Brookfield Renewable
BEPC
+$1.51M
2
WES icon
Western Midstream Partners
WES
+$926K
3
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
+$707K
4
DK icon
Delek US
DK
+$681K
5
CVI icon
CVR Energy
CVI
+$669K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.61M
2
AIMT
Aimmune Therapeutics
AIMT
+$1.13M
3
AIV
Aimco
AIV
+$1.1M
4
VIV icon
Telefônica Brasil
VIV
+$1.01M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$988K

Sector Composition

Rank Sector Weight
1 Healthcare 29.53%
2 Real Estate 18.96%
3 Energy 16.61%
4 Materials 11.31%
5 Utilities 7.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
326
Arcus Biosciences
RCUS
$3.33B
$239K 0.1%
9,188
-1,887
-17% -$45.7K
INBX
327
DELISTED
Inhibrx, Inc. Common Stock
INBX
$235K 0.1%
+7,133
New +$190K
KURA icon
328
Kura Oncology
KURA
$793M
$233K 0.1%
7,136
-11,771
-62% -$414K
QURE icon
329
uniQure
QURE
$2.78B
$230K 0.1%
6,354
+1,461
+30% +$61.6K
RNAM
330
DELISTED
Avidity Biosciences
RNAM
$229K 0.1%
+8,972
New +$262K
ADVM
331
DELISTED
Adverum Biotechnologies
ADVM
$228K 0.09%
2,106
+660
+46% +$81.7K
HRZN icon
332
Horizon Technology Finance
HRZN
$294M
$227K 0.09%
17,125
-981
-5% -$12.2K
FCRD
333
DELISTED
First Eagle Alternative Capital BDC, Inc. Common Stock
FCRD
$226K 0.09%
61,870
-2,438
-4% -$7.74K
BRW
334
Saba Capital Income & Opportunities Fund
BRW
$336M
$223K 0.09%
24,908
-2,145
-8% -$18.9K
EFF
335
DELISTED
EATON VANCE FLOATING-RATE INCOME PLUS FUND
EFF
$221K 0.09%
14,238
-3,281
-19% -$49K
PHAT icon
336
Phathom Pharmaceuticals
PHAT
$928M
$220K 0.09%
6,635
+393
+6% +$15.9K
VXRT
337
DELISTED
Vaxart
VXRT
$218K 0.09%
+38,239
New +$243K
MIRM icon
338
Mirum Pharmaceuticals
MIRM
$6.56B
$215K 0.09%
12,292
-5,166
-30% -$102K
FMTX
339
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$215K 0.09%
+6,168
New +$269K
OXSQ icon
340
Oxford Square Capital
OXSQ
$150M
$213K 0.09%
69,736
-12,232
-15% -$34.6K
OCSI
341
DELISTED
Oaktree Strategic Income Corporation
OCSI
$213K 0.09%
27,535
-4,853
-15% -$34.7K
SAR icon
342
Saratoga Investment
SAR
$309M
$206K 0.09%
9,880
-2,597
-21% -$52.1K
MRCC
343
DELISTED
Monroe Capital Corp
MRCC
$205K 0.09%
25,494
-5,229
-17% -$40.2K
SUNS
344
DELISTED
SLR Senior Investment Corp. Common Stock
SUNS
$202K 0.08%
13,938
-2,362
-14% -$32.8K
TBIO
345
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$202K 0.08%
10,959
-9,640
-47% -$173K
CVAC
346
DELISTED
CureVac
CVAC
$198K 0.08%
+2,437
New +$187K
SCM icon
347
Stellus Capital Investment Corp
SCM
$205M
$198K 0.08%
18,200
-8,255
-31% -$81.7K
BKCC
348
DELISTED
BlackRock Capital Investment Corporation
BKCC
$195K 0.08%
72,371
-6,571
-8% -$17.7K
FIV
349
DELISTED
First Trust Senior Floating Rate 2022 Target Term Fund Common Shares of Beneficial Interest
FIV
$167K 0.07%
18,536
-2,665
-13% -$23.2K
ARCT icon
350
Arcturus Therapeutics
ARCT
$165M
$119K 0.05%
+2,743
New +$186K
11 12 13
14
15

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2020 Portfolio in Review

As of Q4 2020, Virtus ETF Advisers held 372 positions worth $241M, up 26% from $191M the previous quarter. Its ten largest holdings account for 9.4% of the portfolio.

Virtus ETF Advisers deployed $11.8M of net new capital in Q4 2020, opening 47 new positions and adding to 146 existing holdings. Its largest new stake was Harmony Biosciences: 14,899 shares worth $539K.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $572K trimmed.

  • Virtus ETF Advisers's largest Q4 2020 buy was Harmony Biosciences: 14,899 shares worth $539K.
  • Virtus ETF Advisers added most to Brookfield Renewable in Q4 2020, an estimated $1.51M increase.
  • Virtus ETF Advisers's biggest Q4 2020 reduction was Amicus Therapeutics, cutting an estimated $572K.
  • Virtus ETF Advisers fully exited Immunomedics Inc in Q4 2020, selling an estimated $1.61M.
  • Virtus ETF Advisers's ten largest holdings make up 9.4% of its $241M portfolio in Q4 2020.
  • Virtus ETF Advisers opened 47 new positions and closed 17 in Q4 2020.
  • Virtus ETF Advisers's portfolio value rose 26% quarter-over-quarter to $241M.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.